Get started
Avenue Therapeutics, Inc.Avenue Therapeutics, Inc.Avenue Therapeutics, Inc.

Avenue Therapeutics, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

ATXI trade ideas

ATXI reverse split pumpThis is a corporate action where a company reduces the number of its outstanding shares and simultaneously increases the price of each share proportionally. For example, in a 1-for-10 reverse split, if you held 100 shares priced at $1 each, after the split, you would hold 10 shares priced at $10 each. The overall value of your holdings doesn’t change immediately because of the split, but the per-share market price increases. Companies might undertake a reverse split to boost their stock price and avoid being delisted from stock exchanges that have minimum share price requirements.
NASDAQ:ATXILong
by AntonioNaVi
$ATXI (REQUESTED ANALYSIS - I hold no position)Hi, @assafff123 Ok so, personally, I do love Biotech stocks... I don't know why but I love them. The bad news is that there is no support since 2.22 and it broke below that I cannot tell you how low it will go - there's just no support. There are TWO gaps that need to be filled to the UP side (look for the red arrows)... and even if just the first gap fills for now the up side is 108% --- but again I don't know the timeframe until it finds some kind of support... are you comfortable holding? Biotech stocks require a lot of patience. Since there is no support, a fib retracement would put your next place to average down at 0.76 RSI is entering a double bottom - and that is good... I do see a tremendous upside but I can't tell you with any certainty what the timeframe will be... just keep an eye out for the next support level... and add there... and reach out again if you want me to look at it again in the near future...
NASDAQ:ATXI
by SPYder_QQQueen_Trading
1
ATXI nice opportunity?ATXI had the last bullish news on the 20 of november 20, since then, we are only recieving bearish news. We dropped to an significant low and it looks like there is a wide room to climb up again. The only question is when to enter ? Well, it is hard to define due the reason we are on the current all time low, the price could fall further. Anyway I think there is a opportunity if you take a small position or/and wait until it confirms a reversal! Targets mentioned on the chart. Trade safe!
NASDAQ:ATXI
by TradeandGrow
$ATXI can rise in the next daysContextual immersion trading strategy idea. Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. The demand for shares of the company looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $6,29; stop-loss — $4,77. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:ATXILong
by KozakHlib
2
$ATXI GREATER GAINS AHEAD ON PHASE 3 SUCCESSNASDAQ:ATXI TRADED ON HIGH VOLUME AND A INITIAL 30% PRICE SPIKE ON MONDAY BUT SOLD OFF AS THE MARKET CONDITIONS DETERIORATED THROUGHOUT THE DAY. KEEP ON STRONG WATCH AS A MUCH GREATER MOVE IS EXPECTED ON SUCH STRONG RESULTS. COMPANY COMMENTS “The strong safety and efficacy results from this second Phase 3 trial are consistent with those from the first Phase 3 trial in bunionectomy surgery and demonstrated the utility of IV tramadol in post-surgical pain management regardless of the surgery type,” said CEO Lucy Lu in a press release. “This study is a significant milestone for Avenue because it brings us one step closer to submitting a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), currently planned for year-end 2019." AVERAGE ANALYSTS PRICE TARGET $11.67 AVERAGE ANALYSTS RECOMMENDATION BUY COMPANY PROFILE Avenue Therapeutics, Inc. engages in acquiring, licensing, developing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, which is intended for the treatment of moderate to moderately severe post-operative pain. The company was founded on February 9, 2015 and is headquartered in New York, NY.
NASDAQ:ATXILong
by DEXWireNews